DOP2023000038A - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- DOP2023000038A DOP2023000038A DO2023000038A DO2023000038A DOP2023000038A DO P2023000038 A DOP2023000038 A DO P2023000038A DO 2023000038 A DO2023000038 A DO 2023000038A DO 2023000038 A DO2023000038 A DO 2023000038A DO P2023000038 A DOP2023000038 A DO P2023000038A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- sarm1
- sarm1 inhibitors
- inhibitors
- treating
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000038A true DOP2023000038A (es) | 2023-03-15 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000038A DOP2023000038A (es) | 2020-08-24 | 2023-02-23 | Inhibidores de sarm1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (OSRAM) |
| EP (1) | EP4200293A1 (OSRAM) |
| JP (2) | JP7349046B2 (OSRAM) |
| KR (1) | KR20230057396A (OSRAM) |
| AU (2) | AU2021333558C1 (OSRAM) |
| BR (1) | BR112023002575A2 (OSRAM) |
| CA (1) | CA3189181A1 (OSRAM) |
| CL (1) | CL2023000525A1 (OSRAM) |
| CO (1) | CO2023001975A2 (OSRAM) |
| CR (1) | CR20230113A (OSRAM) |
| DO (1) | DOP2023000038A (OSRAM) |
| EC (1) | ECSP23012981A (OSRAM) |
| IL (1) | IL300586A (OSRAM) |
| MX (1) | MX2023002256A (OSRAM) |
| PE (1) | PE20230737A1 (OSRAM) |
| TW (2) | TW202334117A (OSRAM) |
| WO (1) | WO2022046606A1 (OSRAM) |
| ZA (1) | ZA202301801B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| US12404265B2 (en) * | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| JP2024528036A (ja) | 2021-07-28 | 2024-07-26 | ヌラ バイオ，インク． | Ｓａｒｍ１阻害剤としての置換ピリジン誘導体 |
| JP2025523905A (ja) * | 2022-07-21 | 2025-07-25 | アミリックス ファーマシューティカルズ，インコーポレイティッド | オリゴヌクレオチド組成物及びその方法 |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| EP4655069A1 (en) | 2023-01-24 | 2025-12-03 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
| TW202509019A (zh) * | 2023-04-27 | 2025-03-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Sarm1調節子、其製劑及用途 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| DE60332475D1 (de) | 2002-10-30 | 2010-06-17 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
| US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
| CN101472921B (zh) | 2006-06-28 | 2012-10-10 | Aska制药株式会社 | 吡啶基异*唑衍生物 |
| AU2007299261A1 (en) | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| JP2011506563A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | ビスチアゾール誘導体、その製造方法および医薬品としてのその使用 |
| WO2009080694A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| WO2010093849A2 (en) | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| JP6482466B2 (ja) | 2012-11-03 | 2019-03-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| US20160304466A1 (en) | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US11357800B2 (en) | 2016-08-16 | 2022-06-14 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| EP3515426A1 (en) | 2016-09-24 | 2019-07-31 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| UY37512A (es) | 2016-12-09 | 2019-04-30 | Vertex Pharma | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga |
| EP3558986A1 (de) * | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| EP3558976A1 (de) | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| AU2018388406B2 (en) * | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN112839647B (zh) | 2018-06-07 | 2025-09-23 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN112867489A (zh) * | 2018-06-07 | 2021-05-28 | 达萨玛治疗公司 | Sarm1抑制剂 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7470058B2 (ja) * | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
| CN113950326B (zh) | 2019-06-06 | 2025-04-29 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CA3141404A1 (en) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| TW202118392A (zh) | 2019-07-22 | 2021-05-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之５－胺基取代的吡唑及三唑 |
| CN114728007B (zh) | 2019-09-12 | 2025-04-29 | 达萨玛治疗公司 | Sarm1的抑制剂 |
| US20230029266A1 (en) | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| CR20220375A (es) | 2020-01-07 | 2022-09-22 | Disarm Therapeutics Inc | Inhibidores de sarm1 |
| CN116075511B (zh) | 2020-04-09 | 2024-10-29 | 达萨玛治疗公司 | 作为sarm1抑制剂的稠合吡唑衍生物 |
| ES3049432T3 (en) | 2020-04-09 | 2025-12-16 | Disarm Therapeutics Inc | Indazole derivatives as inhibitors of sarm1 |
| US12404265B2 (en) * | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
-
2021
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Pending
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023001975A2 (es) | 2023-03-07 |
| CA3189181A1 (en) | 2022-03-03 |
| AU2021333558A1 (en) | 2023-03-02 |
| KR20230057396A (ko) | 2023-04-28 |
| TW202214597A (zh) | 2022-04-16 |
| MX2023002256A (es) | 2023-03-17 |
| AU2021333558B2 (en) | 2024-02-22 |
| ECSP23012981A (es) | 2023-03-31 |
| EP4200293A1 (en) | 2023-06-28 |
| JP7349046B2 (ja) | 2023-09-21 |
| US20240376083A1 (en) | 2024-11-14 |
| TWI786777B (zh) | 2022-12-11 |
| AU2021333558C1 (en) | 2024-06-20 |
| JP2023535236A (ja) | 2023-08-16 |
| AU2024203373A1 (en) | 2024-06-13 |
| CR20230113A (es) | 2023-04-14 |
| BR112023002575A2 (pt) | 2023-03-07 |
| CL2023000525A1 (es) | 2023-09-15 |
| TW202334117A (zh) | 2023-09-01 |
| TW202530197A (zh) | 2025-08-01 |
| JP7756130B2 (ja) | 2025-10-17 |
| PE20230737A1 (es) | 2023-05-03 |
| WO2022046606A1 (en) | 2022-03-03 |
| US20220056013A1 (en) | 2022-02-24 |
| IL300586A (en) | 2023-04-01 |
| JP2024016014A (ja) | 2024-02-06 |
| US12043613B2 (en) | 2024-07-23 |
| ZA202301801B (en) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000038A (es) | Inhibidores de sarm1 | |
| ECSP22053394A (es) | Inhibidores de sarm1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| BR112023020182A2 (pt) | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| MX2024004162A (es) | Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico. | |
| MX373965B (es) | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). | |
| MX2018003301A (es) | Inhibidores de pcna. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| CO2024015614A2 (es) | Inhibidores de pi3kα | |
| WO2016154329A3 (en) | P38 map kinase inhibitors for treating friedreich's ataxia | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| AR129088A1 (es) | INHIBIDORES DE PI3Ka | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
| EA201890746A1 (ru) | Ингибиторы pcna |